Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297231 | 1.00 | HTR2C (0.56) | HTR2CP2RY14SCN9AMEN1POLB | |
| SCHEMBL6816643 | 0.81 | SLC6A2 (0.55) | HTR2CHTR6 | |
| SCHEMBL19284609 | 0.78 | HTR2C (0.53) | HTR2CHTR6 | |
| SCHEMBL30735659 | 0.78 | HTR2C (0.53) | HTR2CHTR6 | |
| SCHEMBL25145783 | 0.77 | HTR2C (0.59) | HTR2CMEN1POLBKMT2ACHRNB2 | |
| SCHEMBL23858280 | 0.77 | HTR2C (0.59) | HTR2CMEN1POLBKMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL19284700 | 0.77 | HTR2C (0.54) | HTR2CHTR6 | |
| SCHEMBL2710242 | 0.76 | HTR2C (0.56) | HTR2CHTR6 | |
| SCHEMBL30368566 | 0.76 | HTR2C (0.56) | HTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL23858241 | 0.76 | HTR2C (0.60) | HTR2CMEN1POLBKMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | HTR2C 3255/4885P2RY14 3826/4885SCN9A 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.